#### **Supporting Information**

#### **Oleanolic Acid Derivatives as Potential Inhibitors of HIV-1 Protease**

Marta Medina-O'Donnell,<sup>†</sup> Francisco Rivas,<sup>\*,†</sup> Fernando J. Reyes-Zurita,<sup>\*,‡</sup> Mario Cano-Muñoz,<sup>§</sup> Antonio Martinez,<sup>†</sup> Jose A. Lupiañez,<sup>‡</sup> and Andres Parra<sup>\*,†</sup>

<sup>†</sup> Departamento de Química Orgánica, <sup>‡</sup> Departamento de Bioquímica y Biología Molecular I,
<sup>§</sup> Departamento de Química Física, Facultad de Ciencias, Universidad de Granada, E-18071

Granada, Spain

#### **Table of Contents**

Page S3: Figure S1. Dose / response relationships of compounds 1g-4g. Page S4: Figure S2. Dose / response relationships of compounds 5g-8g. Page S5: Figure S3. Dose / response relationships of compounds 9g-12g. Page S6: Figure S4. Dose / response relationships of compounds 2h and 2i. Page S7: Figure S5. 2D schematic representation of the binding interactions of Acetyl-Pepstatin with the active site of the HIV-1 protease. Page S8: Figure S6. Crystallized position of acetyl-pepstatin and the docked position. Page S9: Figure S7. The docking position of acetyl-pepstatin and its molecular surface. Page S10: Figure S8. The 15 top-ranked OA derivatives appear to be linked within the active site of the enzyme. Page S11: Figure S9. Frontal orientation of Figure S8, with a better visualization of the active site of the enzyme. Page S12: Figure S10. The best docking position for compound 11g and its molecular surface. Page S13: Figure S11. Superimposition of the structures of acetyl-pepstatin and compound 11g denoting a similar binding domain, mainly within the active site of the HIV-1 protease. Page S14: Figure S12. <sup>1</sup>H, <sup>13</sup>C NMR spectra and DEPT of compound 1g (CDCl<sub>3</sub>). Page S15: Figure S13. <sup>1</sup>H, <sup>13</sup>C NMR spectra and DEPT of compound 2g (CDCl<sub>3</sub>). Page S16: Figure S14. <sup>1</sup>H, <sup>13</sup>C NMR spectra and DEPT of compound 2h (CDCl<sub>3</sub>). Page S17: Figure S15. <sup>1</sup>H, <sup>13</sup>C NMR spectra and DEPT of compound 2i (CDCl<sub>3</sub>). Page S18: Figure S16. <sup>1</sup>H, <sup>13</sup>C NMR spectra and DEPT of compound 3g (CDCl<sub>3</sub>). Page S19: Figure S17. <sup>1</sup>H, <sup>13</sup>C NMR spectra and DEPT of compound 4g (CDCl<sub>3</sub>). Page S20: Figure S18. <sup>1</sup>H, <sup>13</sup>C NMR spectra and DEPT of compound 5g (CDCl<sub>3</sub>). Page S21: Figure S19. <sup>1</sup>H, <sup>13</sup>C NMR spectra and DEPT of compound 6g (CDCl<sub>3</sub>). Page S22: Figure S20. <sup>1</sup>H, <sup>13</sup>C NMR spectra and DEPT of compound 7g (CDCl<sub>3</sub>). Page S23: Figure S21. <sup>1</sup>H, <sup>13</sup>C NMR spectra and DEPT of compound 8g (CDCl<sub>3</sub>). Page S24: Figure S22. <sup>1</sup>H, <sup>13</sup>C NMR spectra and DEPT of compound 9g (CDCl<sub>3</sub>). Page S25: Figure S23. <sup>1</sup>H, <sup>13</sup>C NMR spectra and DEPT of compound 10g (CDCl<sub>3</sub>). Page S26: Figure S24. <sup>1</sup>H, <sup>13</sup>C NMR spectra and DEPT of compound 11g (CDCl<sub>3</sub>). Page S27: Figure S25. <sup>1</sup>H, <sup>13</sup>C NMR spectra and DEPT of compound 12g (CDCl<sub>3</sub>).



Figure S1. Dose / response relationships of compounds 1g-4g, expressed in percentages of activity of these compounds at different concentrations ( $\mu$ M). Values represent means of an experiment performed in triplicate.



Figure S2. Dose / response relationships of compounds 5g-8g, expressed in percentages of activity of these compounds at different concentrations ( $\mu$ M). Values represent means of an experiment performed in triplicate.

Figure S3. Dose / response relationships of compounds 9g-12g, expressed in percentages of activity of these compounds at different concentrations ( $\mu$ M). Values represent means of an experiment performed in triplicate.



Figure S4. Dose / response relationships of compounds 2h and 2i, expressed in percentages of activity of these compounds at different concentrations ( $\mu$ M). Values represent means of an experiment performed in triplicate.



**Figure S5**. 2D schematic representation of the binding interactions of Acetyl-Pepstatin with the active site of the HIV-1 protease, created with PoseView.



The H-bonds are shown as black dashed lines, and residue labels and spline segments along the contacting hydrophobic ligand parts represent the hydrophobic contacts.

**Figure S6**. Crystallized position of acetyl-pepstatin (red sticks) and the docked position (green sticks) showing a good correlation between the two, as a positive control to validate the docking protocol.



**Figure S7**. The docking position of acetyl-pepstatin (green sticks) and its molecular surface (translucent green), indicating the location of the active site.



**Figure S8**. The 15 top-ranked OA derivatives (rainbow sticks) appear to be linked within the active site of the enzyme.



Figure S9. Frontal orientation of Figure S8, with a better visualization of the active site of the enzyme.



Figure S10. The best docking position for compound 11g (blue sticks) and its molecular surface (translucent blue).



**Figure S11**. Superimposition of the structures of acetyl-pepstatin and compound **11g** denoting a similar binding domain, mainly within the active site of the HIV-1 protease.





Figure S12. <sup>1</sup>H, <sup>13</sup>C NMR spectra and DEPT of compound 1g (CDCl<sub>3</sub>).







Figure S14. <sup>1</sup>H, <sup>13</sup>C NMR spectra and DEPT of compound **2h** (CDCl<sub>3</sub>).



Figure S15. <sup>1</sup>H, <sup>13</sup>C NMR spectra and DEPT of compound 2i (CDCl<sub>3</sub>).



# Figure S16. <sup>1</sup>H, <sup>13</sup>C NMR spectra and DEPT of compound **3g** (CDCl<sub>3</sub>).



# Figure S17. <sup>1</sup>H, <sup>13</sup>C NMR spectra and DEPT of compound 4g (CDCl<sub>3</sub>).



Figure S18. <sup>1</sup>H, <sup>13</sup>C NMR spectra and DEPT of compound 5g (CDCl<sub>3</sub>).



Figure S19. <sup>1</sup>H, <sup>13</sup>C NMR spectra and DEPT of compound 6g (CDCl<sub>3</sub>).



# Figure S20. <sup>1</sup>H, <sup>13</sup>C NMR spectra and DEPT of compound 7g (CDCl<sub>3</sub>).



Figure S21. <sup>1</sup>H, <sup>13</sup>C NMR spectra and DEPT of compound 8g (CDCl<sub>3</sub>).



Figure S22. <sup>1</sup>H, <sup>13</sup>C NMR spectra and DEPT of compound **9g** (CDCl<sub>3</sub>).



Figure S23. <sup>1</sup>H, <sup>13</sup>C NMR spectra and DEPT of compound 10g (CDCl<sub>3</sub>).



# Figure S24. <sup>1</sup>H, <sup>13</sup>C NMR spectra and DEPT of compound 11g (CDCl<sub>3</sub>).



# Figure S25. <sup>1</sup>H, <sup>13</sup>C NMR spectra and DEPT of compound **12g** (CDCl<sub>3</sub>).